Urinary Tract Infection Market Analysis and Forecast

Urinary tract infection is one of the most prevalent types of infections globally, with nearly 150 million people being annually diagnosed with some type of urinary tract infections (UTI). Over the years, there has been a considerable rise in home remedies and surgical operations undertaken for treating urinary tract infection. Being more prevalent in women, physicians are demanding a regular supply of drugs for treating female patients infected urinary tract disorders.

In a year, about 10% of women develop urinary tract infection in the form of bacterial infection. The prominence of bladder infection in women and kidney infection in men makes treatment for urinary tract infection calls for effective treatment mechanisms that are safe, robust, and affordable.                                                          

Physicians and surgical staff rely on availability of drugs like penicillin and other drugs providing antibiotic resistance towards urinary tract infection. The global market for urinary tract infection treatment has witnessed this growing demand for instruments and pharmaceutical drugs that cure bladder-related infections. In 2016, the expected reach for global urinary tract infection treatment market is estimated to be US$ 9.42 Bn in terms of revenues. A decade-long forecast for the market is anticipating growth at the CAGR of 2.1%. By the end of 2026, the global UTI treatment market is likely to attain revenue worth over US$ 11.5 Bn.

Status of Urinary Tract Infection Treatments

Bladder infections and kidney infections are spreading rampantly in every part of the world. Unavailability of potable water, dehydration caused due to exhaustive lifestyle and excessive consumption of unhealthy drinks and aerated beverages are the most common factors that cause urinary tract infections. Dietary habits involving intake of fruit and vegetable juices in abundance are also responsible for getting diagnosed with complications in urinary tract. Demographics of regions like Asia Pacific excluding Japan (APEJ) are more affected with complicated urinary infections. The UTI treatment market in APEJ has a dominant status in the global UTI market. The revenues generated in this region are likely to total at US$ 3.46 Bn by 2016-end.

Increase in the number of people getting diagnosed with UTI results in an increase in the demand for treatment apparatus and drugs. Antibiotic drugs are most commonly used to treat several types of bladder and kidney infections. The growing demand for antibiotics proves profitable for distribution channels like pharmacies and drugstore.

The urinary tract infection treatment market has positive effects on healthcare and pharmaceuticals sector. Besides the growing sales of these drugs, ailments derived from urinary tract infections are also related for being symptoms of common disorders like diabetes mellitus. Companies like Johnson & Johnson, Cipla Ltd., Novartis AG, Roche Ltd., and Pfizer Inc. are the leading competitors using variable strategies like advancements in existing drugs or acquisition of top pharmaceutical manufactures to stimulate global growth of urinary tract infection treatment market.